Hypoxia-activated 2-nitroimidazole-brusatol carbonate prodrugs for enhanced gastric cancer therapy with reduced systemic toxicity.
Tumor hypoxia, a characteristic feature of solid tumors that induces chemoresistance, enables the rational design of tumor-selective prodrugs. Brusatol (BST), a natural quassinoid with broad-spectrum antitumor effects, faces obstacles to clinical translation due to high systemic toxicity and insufficient tumor selectiv...